81 related articles for article (PubMed ID: 3053941)
1. Study of capillary filtration by double labelling I131-albumin and Tc99m red cells. Application to the pharmacodynamic activity of Daflon 500 mg.
Behar A; Lagrue G; Cohen-Boulakia F; Baillet J
Int Angiol; 1988; 7(2 Suppl):35-8. PubMed ID: 3053941
[TBL] [Abstract][Full Text] [Related]
2. Effects of a purified micronized flavonoid fraction on capillary filtration in diabetic patients.
Valensi PE; Behar A; de Champvallins MM; Attalah M; Boulakia FC; Attali JR
Diabet Med; 1996 Oct; 13(10):882-8. PubMed ID: 8911782
[TBL] [Abstract][Full Text] [Related]
3. Capillary filtration in idiopathic cyclic edema--effects of Daflon 500 mg.
Behar A; Lagrue G; Cohen-Boulakia F; Baillet J
Nuklearmedizin; 1988 Jun; 27(3):105-7. PubMed ID: 3043383
[No Abstract] [Full Text] [Related]
4. Are the phlebotonic properties shown in clinical pharmacology predictive of a therapeutic benefit in chronic venous insufficiency? Our experience with Daflon 500 mg.
Tsouderos Y
Int Angiol; 1989; 8(4 Suppl):53-9. PubMed ID: 2698902
[TBL] [Abstract][Full Text] [Related]
5. Capillary filtration and lymphatic resorption in diabetes. Application to the pharmacodynamic activity of Daflon 500 mg.
Behar A; Valensi P; de Champvallins M; Cohen-Boulakia F; Albagli B
Int Angiol; 1989; 8(4 Suppl):27-9. PubMed ID: 2632646
[TBL] [Abstract][Full Text] [Related]
6. In vivo sequential study of skeletal muscle capillary permeability in diabetic rats: effect of anthocyanosides.
Cohen-Boulakia F; Valensi PE; Boulahdour H; Lestrade R; Dufour-Lamartinie JF; Hort-Legrand C; Behar A
Metabolism; 2000 Jul; 49(7):880-5. PubMed ID: 10909999
[TBL] [Abstract][Full Text] [Related]
7. [Determination of capillary permeability with labeled human albumin].
Behar AA; Tournoux JB; Lagrue G
Nuklearmedizin; 1976 Oct; 15(5):214-6. PubMed ID: 1005127
[TBL] [Abstract][Full Text] [Related]
8. Clinical evaluation of a venotropic drug in man. Example of Daflon 500 mg.
Laurent R; Gilly R; Frileux C
Int Angiol; 1988; 7(2 Suppl):39-43. PubMed ID: 3053942
[TBL] [Abstract][Full Text] [Related]
9. Double blind study of the pharmacodynamic and clinical activities of 5682 SE in venous insufficiency. Advantages of the new micronized form.
Cospite M; Dominici A
Int Angiol; 1989; 8(4 Suppl):61-5. PubMed ID: 2698903
[TBL] [Abstract][Full Text] [Related]
10. A double-blind, placebo-controlled trial of a new veno-active flavonoid fraction (S 5682) in the treatment of symptomatic capillary fragility.
Galley P; Thiollet M
Int Angiol; 1993 Mar; 12(1):69-72. PubMed ID: 8376915
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the clinical pharmacological activity of a phlebotonic agent. Application to the study of Daflon 500 mg.
Duchene Marullaz P; Amiel M; Barbe R
Int Angiol; 1988; 7(2 Suppl):25-32. PubMed ID: 3053940
[TBL] [Abstract][Full Text] [Related]
12. Advantage of a micronized flavonoidic fraction (Daflon 500 mg) in comparison with a nonmicronized diosmin.
Amato C
Angiology; 1994 Jun; 45(6 Pt 2):531-6. PubMed ID: 8203783
[TBL] [Abstract][Full Text] [Related]
13. Venous tone: are the phlebotonic properties predictive of a therapeutic benefit? A comprehensive view of our experience with Daflon 500 mg.
Tsouderos Y
Z Kardiol; 1991; 80 Suppl 7():95-101. PubMed ID: 1792820
[TBL] [Abstract][Full Text] [Related]
14. Clinical implications of impaired microcirculation.
Valensi P; Behar A
Int Angiol; 1995 Sep; 14(3 Suppl 1):26-31. PubMed ID: 8919261
[TBL] [Abstract][Full Text] [Related]
15. Controlled studies of Daflon 500 mg in chronic venous insufficiency.
Geroulakos G; Nicolaides AN
Angiology; 1994 Jun; 45(6 Pt 2):549-53. PubMed ID: 8203786
[TBL] [Abstract][Full Text] [Related]
16. [Study of the pharmacodynamic activity of daflon 500 mg].
Amiel M; Barbe R
Ann Cardiol Angeiol (Paris); 1998 Mar; 47(3):185-8. PubMed ID: 9772947
[TBL] [Abstract][Full Text] [Related]
17. Hemorheological improvement after Daflon 500 mg treatment in diabetes.
Lacombe C; Bucherer C; Lelievre JC
Int Angiol; 1988; 7(2 Suppl):21-4. PubMed ID: 3183453
[TBL] [Abstract][Full Text] [Related]
18. Double-blind, placebo-controlled evaluation of clinical activity and safety of Daflon 500 mg in the treatment of acute hemorrhoids.
Cospite M
Angiology; 1994 Jun; 45(6 Pt 2):566-73. PubMed ID: 8203789
[TBL] [Abstract][Full Text] [Related]
19. [Evaluation of clinical efficacy of a venotonic drug: lessons of a therapeutic trial with hemisynthesis diosmin in "heavy legs syndrome"].
Carpentier PH; Mathieu M
J Mal Vasc; 1998 Apr; 23(2):106-12. PubMed ID: 9608923
[TBL] [Abstract][Full Text] [Related]
20. Daflon 500 mg in the treatment of hemorrhoidal disease: a demonstrated efficacy in comparison with placebo.
Godeberge P
Angiology; 1994 Jun; 45(6 Pt 2):574-8. PubMed ID: 8203790
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
